Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04708171

The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections

Status
Recruiting
Phase
Study type
Observational
Enrollment
453 (estimated)
Sponsor
Erasmus Medical Center · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

The study is designed as an international, multicenter prospective cohort study. Patients with presumed glioblastoma (GBM) in- or near eloquent areas on diagnostic MRI will be selected by neurosurgeons. Patients will be treated following one of three study arms: 1) a craniotomy where the resection boundaries for motor or language functions will be identified by the "awake" mapping technique (awake craniotomy, AC); 2) a craniotomy where the resection boundaries for motor functions will be identified by "asleep" mapping techniques (MEPs, SSEPs, continuous dynamic mapping); 3) a craniotomy where the resection boundaries will not be identified by any mapping technique ("no mapping group"). All patients will receive follow-up according to standard practice.

Conditions

Interventions

TypeNameDescription
PROCEDUREAwake mapping under local anesthesiaDuring an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
PROCEDUREAsleep mapping under general anesthesiaDuring asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
PROCEDUREResection under general anesthesia without mappingDuring resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.

Timeline

Start date
2022-01-01
Primary completion
2025-10-01
Completion
2026-10-01
First posted
2021-01-13
Last updated
2022-05-06

Locations

8 sites across 5 countries: United States, Belgium, Germany, Netherlands, Switzerland

Source: ClinicalTrials.gov record NCT04708171. Inclusion in this directory is not an endorsement.